IQVIA’s first quarter results were positively received by the market, reflecting stronger-than-expected revenue growth and solid execution in both its Commercial and R&D Solutions segments. Management attributed this outperformance to increased client demand across core offerings, particularly in areas integrating artificial intelligence and analytics. CEO Ari Bousbib highlighted that, “our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled,” compared to a year ago, with notable momentum in Patient Solutions and Analytics and Consulting. The company’s ability to secure large, multiyear contracts with leading pharmaceutical clients and to embed AI across business lines were key factors supporting robust top and bottom line performance.
Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).
IQVIA (IQV) Q1 CY2026 Highlights:
- Revenue: $4.15 billion vs analyst estimates of $4.10 billion (8.4% year-on-year growth, 1.1% beat)
- Adjusted EPS: $2.90 vs analyst estimates of $2.82 (3% beat)
- Adjusted EBITDA: $932 million vs analyst estimates of $926.4 million (22.5% margin, 0.6% beat)
- The company reconfirmed its revenue guidance for the full year of $17.25 billion at the midpoint
- Management slightly raised its full-year Adjusted EPS guidance to $12.80 at the midpoint
- EBITDA guidance for the full year is $4 billion at the midpoint, in line with analyst expectations
- Operating Margin: 12.4%, in line with the same quarter last year
- Constant Currency Revenue rose 6% year on year (3.5% in the same quarter last year)
- Market Capitalization: $28.97 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From IQVIA’s Q1 Earnings Call
- Leerink Partners asked how the mix shift toward full-service bookings versus pass-throughs would affect future margins. CEO Ari Bousbib clarified that pass-throughs have no profit impact and that recent booking mix was a one-off event, not a new trend.
- Justin Bowers (Deutsche Bank) questioned if the change in booking mix signals a shift in client strategy or affects margin outlook. Bousbib reiterated that the mix was driven by specific trial types this quarter, not a broader shift, and CFO Michael Fedock added that operational productivity offset any negative mix effects.
- Barclays sought more details on Commercial Solutions’ outperformance and recurring revenue mix. Bousbib explained that strong demand for AI-enabled analytics and patient solutions, alongside robust pipelines, drove organic growth and that recurring information services remain a stable base.
- Shlomo Rosenbaum (Stifel) asked whether IQVIA’s growth was indicative of a broader industry recovery. Bousbib responded that improved client sentiment and funding levels are supporting demand, especially as AI becomes more central to pharma R&D and commercialization.
- Elizabeth Hammell Anderson (Evercore ISI) inquired about EBITDA margin progression for the rest of the year. Fedock replied that margin trends are consistent with historical patterns, with productivity initiatives expected to offset currency-related headwinds over time.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will be watching (1) how quickly IQVIA’s AI solutions gain traction across key pharma clients, (2) the pace at which large contracts and backlog convert into realized revenue, and (3) the company’s ability to manage margin pressures from currency and business mix. Ongoing developments in biotech funding and client R&D pipelines will also be important indicators of future performance.
IQVIA currently trades at $174.26, up from $160.94 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
